Results 41 to 50 of about 125,484 (349)

Pharmacology of proton pump inhibitors [PDF]

Current Gastroenterology Reports, 2008
The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are weak bases composed of two moieties, a substituted pyridine with a primary pK(a) of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole with a second pK(a) of about ...
Jai Moo Shin, George Sachs
openaire   +3 more sources

Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease : cost effectiveness study [PDF]

, 2009
Peer reviewedPublisher ...
Bojke, Laura, Campbell, Marion K, Epstein, David, REFLUX Trial Group, Sculpher, Mark J   +4 more
core   +2 more sources

Refractory gastroesophageal reflux disease

Arquivos de Gastroenterologia, 2012
CONTEXT: Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications.
Joaquim Prado P. Moraes-Filho
doaj   +1 more source

Proton Pump Inhibitors Therapy in Children with Gastroesophageal Reflux [PDF]

, 2013
Proton pump inhibitors (PPI) has been widely used by clinicians to treat diseases that require suppression of gastric acid. PPI work by inhibiting the proton pump in gastric parietal cells.In adult patients, PPI hasbeen widely studied and showed ...
Hegar, B. (Badriul), Reynaldo, A. (Aldo)
core  

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

Proton Pump Inhibitors: Are They a Real Threat to the Patient?

GE: Portuguese Journal of Gastroenterology, 2018
Background: Proton pump inhibitors are among the most frequently prescribed drugs in the world and are generally considered safe. However, there is growing concern regarding their safety.
Sofia Xavier, Joana Magalhães, José Cotter   +2 more
doaj   +1 more source

Prevalence of proton pump inhibitors drug interactions in community pharmacy: a network analysis approach.

Jornal de Assistência Farmacêutica e Farmacoeconomia, 2023
Objective: The aim of this study is to identify the prevalence of drug interaction associated with proton pump inhibitors, associated factors and drugs involved.
Lorena Maria Lima de Araujo, Júlia Scarlet Batista Oliveira, Maria Vivyanne de Moura Lopes, Rafael Silva de Arruda, Antonio Gouveia Oliveira, Rand Randall Martins   +5 more
doaj   +1 more source

Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease : systematic review. [PDF]

, 2003
Objectives: To ascertain the prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease and its association with the disease.
Childs, S., Hungin, A. P. S., Raghunath, A., Wooff, D.   +3 more
core   +2 more sources

Iron‐dependent lysosomal LDL oxidation induces the expression of scavenger receptor A in human THP‐1 monocytes

FEBS Open Bio, EarlyView.
In human monocytic cells THP‐1, a limited uptake of native—not oxidized—LDL/VLDL induced expression of scavenger receptor A and cellular adhesion. Induction was inhibited by lysosomotropic (WR‐1065) and lipophilic (BHT) antioxidants and by siRNAs against ferritinophagy.
Martina Čierna, Richard Buchal, Martin Leníček, Amit Shachak, Jan Pláteník   +4 more
wiley   +1 more source

ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW

Arquivos de Gastroenterologia, 2017
BACKGROUND: Proton pump inhibitors and histamine H2 receptor antagonists are two of the most commonly prescribed drug classes for pediatric gastroesophageal reflux disease, but their efficacy is controversial.
Ângelo Zambam de MATTOS, Gabriela Meirelles MARCHESE, Bárbara Brum FONSECA, Carlos KUPSKI, Marta Brenner MACHADO   +4 more
doaj   +1 more source